GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (NAS:XOMA) » Definitions » EBITDA per Share

XOMA (XOMA) EBITDA per Share

: $-3.43 (TTM As of Dec. 2023)
View and export this data going back to 1986. Start your Free Trial

XOMA's EBITDA per Share for the three months ended in Dec. 2023 was $-2.08. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.43.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for XOMA's EBITDA per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of XOMA was 91.50% per year. The lowest was -568.10% per year. And the median was 10.85% per year.

XOMA's 3-Year EBITDA Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 6.1
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

XOMA's EBITDA for the three months ended in Dec. 2023 was $-23.83 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of XOMA was 90.30% per year. The lowest was -628.60% per year. And the median was -4.30% per year.


XOMA EBITDA per Share Historical Data

The historical data trend for XOMA's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA per Share
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 1.19 1.34 -1.49 -3.43

XOMA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.51 -0.36 -0.49 -2.08

XOMA EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

XOMA's EBITDA per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA per Share(A: Dec. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-39.362/11.471
=-3.43

XOMA's EBITDA per Share for the quarter that ended in Dec. 2023 is calculated as

EBITDA per Share(Q: Dec. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-23.83/11.486
=-2.07

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA  (NAS:XOMA) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


XOMA EBITDA per Share Related Terms

Thank you for viewing the detailed overview of XOMA's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA (XOMA) Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Executives
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Thomas M. Burns officer: Chief Financial Officer 2910 SEVENTH STREET, BERKELEY CA 94710
James R Neal officer: VP Business Development 2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman director C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian director, officer: Director and CEO ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Matthew D Perry director, other: See Explanation of Responses ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104

XOMA (XOMA) Headlines

From GuruFocus

XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 01-07-2023

XOMA Declares Quarterly Preferred Stock Dividends

By Tiesvg Tiesvg 12-22-2022

XOMA Declares Quarterly Preferred Stock Dividends

By GuruFocusNews GuruFocusNews 07-10-2022

XOMA to Present at H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 07-06-2022

XOMA to Present at H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-17-2022

XOMA Declares Quarterly Preferred Stock Dividends

By sperokesalga sperokesalga 03-21-2023

XOMA Declares Quarterly Preferred Stock Dividends

By GuruFocusNews GuruFocusNews 06-20-2022

XOMA to Present at H.C. Wainwright BioConnect Investor Conference

By sperokesalga sperokesalga 04-26-2023